Skip to main content
Premium Trial:

Request an Annual Quote

EliTech to Distribute Curetis Unyvero Products in Belgium, Luxembourg

NEW YORK (GenomeWeb News) – Molecular diagnostics company Curetis today announced a deal with EliTech BNL to distribute its products in Belgium and Luxembourg.

Terms of the deal were not disclosed.

EliTech BNL, formerly call Lucron Bioproducts, is part of the EliTech Group and supported Cepheid's entry into the Benelux market, Curetis said.

"Having built a successful business for Cepheid and the GeneXpert system in the Benelux, we are excited about the opportunity presented by the Curetis Unyvero Solution," Frank Loots, general manager of EliTech BNL, said in a statement. "We are planning a commercial rollout and market introduction phase here in Belgium and in Luxembourg to begin with leading clinicians and institutions in our territories."

Curetis' PCR-based Unyvero System enables DNA-based testing for the detection of a broad panel of bacteria and antibiotic resistance from a single sample in one run. The first CE-marked Unyvero Cartridge simultaneously analyzes 39 DNA targets for pneumonia testing, and another Unyvero application for implant and tissue infections is in product development, Curetis said.

The Holzgerlingen, Germany-based company said in December it anticipates filing a 510(k) application with the US Food and Drug Administration for the Unyvero System in 2014 and began a clinical trial for the platform and its lower respiratory tract application.

Curetis today also announced it has hired Helmut Hilbert as head of business development. Hilbert was formerly with Qiagen.

The Scan

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.

Study Points to Synonymous Mutation Effects on E. Coli Enzyme Activity

Researchers in Nature Chemistry saw signs of enzyme activity shifts in the presence of synonymous mutations in a multiscale modeling analysis of three Escherichia coli genes.

Team Outlines Paternal Sample-Free Single-Gene Approach for Non-Invasive Prenatal Screening

With data for nearly 9,200 pregnant individuals, researchers in Genetics in Medicine demonstrate the feasibility of their carrier screening and reflex single-gene non-invasive prenatal screening approach.

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.